In recent years, the wide use of direct antiviral agents for the treatment of Hepatitis C and nucleos(t)ide analogues with a high genetic barrier for hepatitis B have reduced the indication of liver transplantation (LT) in these diseases. Recurrence of autoimmune-mediated liver diseases, including autoimmune hepatitis, primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC) post-LT, is usually a late event and can be difficult to diagnose, often requiring a liver biopsy. It is important to tailor immunosuppression to account for the autoimmune background; these patients often require higher doses or combination therapy. In PSC, consideration of associated inflammatory bowel disease must be given. In PBC, preemptive use of ursodeoxycholic acid may prevent, or at least delay, recurrent disease. Alcohol relapse is frequent post-LT and may result in impaired survival. Early LT is associated with a slightly increased risk of alcohol relapse compared with a mandatory 6-month abstinence period. A multidisciplinary approach has been shown to improve outcomes by addressing psychosocial factors and implementing tailored interventions.